Retrophin (RTRX) Announces Appointment Of Gary Lyons To Board Of Directors
NEW YORK--(BUSINESS WIRE)--Retrophin, Inc. (NASDAQ:RTRX) today announced the appointment of Gary Lyons to the Board of Directors as a third independent director. This addition brings the Company into compliance with the independent director and audit committee requirements set forth in Nasdaq Listing Rule 5605.
"I'm pleased to welcome Gary to our board of directors," said Stephen Aselage, Chief Executive Officer of Retrophin. "He has extensive biopharmaceutical expertise that will contribute to Retrophin's success and help accelerate our growth through the advancement of our pipeline and pursuit of business development opportunities."